Roles of UDP-glucuronosyltransferases in phytochemical metabolism of herbal medicines and the associated herb-drug interactions

Current Drug Metabolism

Volumn 13, Issue 5, 2012, Pages 615-623

  Li, Li ^a   Hu, Haihong ^a   Xu, Siyun ^a   Zhou, Quan ^a   Zeng, Su ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Glucuronidation; Herb drug interaction; Herbal medicines; UDP glucuronosyltransferase

Indexed keywords

ANDROSTANOLONE; AVICULARINE; CATECHOL DERIVATIVE; CHRYSIN; CYTOCHROME P450; CYTOCHROME P450 2B4; DAIDZEIN; EBRACTEOLATA COMPOUND B; FIRTECAN; GENISTEIN; GLUCURONIC ACID; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B7; GLYCYRRHETINIC ACID; HYPERICIN; HYPERICUM PERFORATUM EXTRACT; IRINOTECAN; ISOFLAVONE DERIVATIVE; KAEMPFEROL; MORIN; MYCOPHENOLIC ACID; QUERCETIN; SILIBININ; TESTOSTERONE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; DEALKYLATION; DRUG CONJUGATION; DRUG METABOLISM; DRUG STRUCTURE; GINKGO BILOBA; GLUCURONIDATION; HERB DRUG INTERACTION; HERBAL MEDICINE; HUMAN; HYDROXYLATION; HYPERICUM PERFORATUM; IC 50; LIVER MICROSOME; NONHUMAN; OROXYLUM; PHYTOCHEMISTRY; SINGLE NUCLEOTIDE POLYMORPHISM; TEA;

EID: 84861845471     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/1389200211209050615     Document Type: Article

References (120)

1. De Smet, P.A. Herbal medicine in Europe-relaxing regulatory standards. N. Eng. J. Med., 2005, 352(12), 1176-1178.
2. Ernst, E; Pittler, M.H. Herbal medicine. Med. Clin. North Am., 2002, 86(1), 149-161.
3. Dog, T.L. The use of botanicals during pregnancy and lactation. Altern. Ther. Health.Med., 2009, 15(1), 54-58.
4. Ernst, E; Cassileth, B.R. The prevalence of complementary alternative medicine in cancer: a systematic review. Cancer, 1998, 83(4), 777-782.
5. Roy, A.; Lurslurchachai, L.; Halm ,E.A.; Li, X.M.; Leventhal, H.; Wisnivesky, J.P. Use of herbal remedies and adherence to inhaledcorticosteroids among inner-city asthmatic patients. Ann. Allergy Asthma Immunol., 2010, 104(2), 132-138.
6. Bent, S. Herbal medicine in the United States: review of efficacy,safety, and regulation: grand rounds at University of California,San Francisco Medical Center. J. Gen. Intern. Med., 2008, 23(6), 854-859.
7. Ernst, E. The current position of complementary/alternative medicine in cancer. Eur. J. Cancer, 2003, 39(16), 2273-2277.
8. Ernst, E. The role of complementary and alternative medicine incancer. Lancet Onco., 2000, 1, 176-180.
9. Jordan, S.A.; Cunningham, D.G.; Marles, R.J. Assessment of herbalmedicinal products: challenges, and opportunities to increase the knowledge base for safety assessment. Toxicol. Appl. Pharmacol., 2010, 243(2), 198-216.
10. Ernst, E. The risk-benefit profile of commonly used herbaltherapies: Ginkgo, St. John'sWort, Ginseng, Echinacea, SawPalmetto, and Kava. Ann. Intern. Med., 2002, 136(1), 42-53.
11. Qiu, J. China plans to modernize traditional medicine. Nature, 2007, 446(7136), 590-591.
12. He, S.M.; Li, C.G.; Liu, J.P.; Chan, E.; Duan, W.; Zhou, S.F. Dispositionpathways and pharmacokinetics of herbal medicines in humans. Curr. Med. Chem., 2010, 17(33), 4072-113.
13. Vlietinc, K.A; Pieters, L; Apers, S. Legal requirements for the quality of herbal substances and herbal preparations for the manufacturingof herbal medicinal products in the European union. Planta Med., 2009, 75(7), 683-688.
14. Zhou, S.F.; Zhou, Z.W.; Huang, M. Pharmacokinetics and disposition of plant natural products in humans and the clinical andtoxicological implications. Curr. Org. Chem., 2010, 14(16), 1732-1756.
15. Glue, P.; Clement, R.P. Cytochrome P450 Enzymes and drug metabolism-basic concepts and methods of assessment. Cell Mol. Neurobiol., 1999, 19(3), 309-323.
16. Miller, E.C.; Lotlikar, P.D.; Miller, J.A.; Butler, B.W.; Irving, C.C.; Hill J.T. Reactions in vitro of some tissue nucleophiles with the glucuronide of the carcinogenN-hydroxy-2-acetylaminofluorene, Mol. Pharmacol., 1968, 4(2), 147-154.
17. Paul, D.; Standifer, K.M., Inturrisi, C.E.; Pasternak, G.W. Pharmacological characterization of morphine-6-beta-glucuronide, a very potent morphine metabolite. J. Pharmacol. Exp. Ther., 1989, 251(2), 477-483.
18. King, C.D.; Rios, G.R.; Green, M.D. UDP-Glucuronosyltransferases. Curr. Drug Metab., 2000, 1(2), 143-161.
19. Tukey, R.; Strassburg, C. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu. Rev. Pharmacol. Toxicol., 2000, 40, 581-616.
20. Mackenzie, P.I, Owens, I.S.; Burchell, B.; Bock, K.W.; Bairoch, A.; Belanger, A.; The UDPglycosyl transferasegene superfamily: recommendednomenclature update based on evolutionarydivergence. Pharmacogenetics, 1997, 7(4), 255-269.
21. Guillemette, C. Pharmacogenomics of human UDPglucuronosyltransferase enzymes. Pharmacogenomics, 2003(1), 3, 136-158.
22. Chen, Y.K.; Chen, S.Q; Li, X.; Wang, X.W; Zeng, S. Genetic Variants of Human UGT1A3: Functional Characterization and Frequency Distribution in a Chinese Han Population. Drug Metab. Dispos., 2006, 34(9), 1462-1467.
23. Gagne, J.F.; Montminy, V.; Belanger, P.; Journault, K.; Gaucher, G.; Guillemette, C. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10- hydroxycamptothecin (SN-38). Mol. Pharmacol., 2002, 62(3), 608-617.
24. Paoluzzi, L.;Singh, A.S.;Price, D.K.;Danesi, R.;Mathijssen, R.H.J.; Verweij, J.; Figg, W.D.; Sparreboom, A. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J. Clin. Pharmacol., 2004, 44(8), 854-860.
25. Vogel, A.; Kneip, S.; Barut, A.; Ehmer, U.; Tukey, R.H.; Manns, M.P.; Strassburg, C.P. Genetic link of hepatocellular carcinoma with polymorphisms of the UDP-glucuronosyltransferase UGTIA7 gene. Gastroenterol., 2001, 121(5), 1136-1144.
26. Zhou, S.F.; Xue, C.C.; Yu, X.Q.; Wang, G. Metabolic activation ofherbal and dietary constituents and its clinical and toxicologicalimplications: an update. Curr. Drug Metab., 2007, 8(6), 526-553.
27. Zhou, S.; Koh, H.L.; Gao, Y.; Gong, Z.Y.; Lee, E.J. Herbal bioactivation: the good, the bad and the ugly. Life Sci., 2004, 74(8), 935-968.
28. White, C.P; Hirsch, G.; Patel, S.; Adams, F.; Peltekian, K.M. Complementary and alternative medicine use by patients chronically infected with hepatitisC virus. Can. J. Gastroenterl., 2007, 21(9), 589-595.
29. Miller, M.F; Bellizzi, K.M.; Sufian, M.; Ambs, A.H.; Goldstein, M.S.; Ballard-Barbash R. Dietary supplement use in individuals living with cancer andother chronic conditions: a population-based study. J. Am. Diet. Assoc., 2008, 108(3),483-494.
30. Eisenberg, D.M.; Davis, R.B.; Ettner, S.L.; Appel, S.; Wilkey, S.; Van. Rompay M.; Kessler, R.C. Trends in alternative medicine use in the United States,1990-1997: results of a follow-up national survey. JAMA., 1998, 280(18), 1569-1575.
31. Bardia, A.; Nisly, N.L; Zimmerman, M.B; Gryzlak ,B.M; Wallace, R.B. Use of herbs among adults based on evidence-based indications: findings from the National Health Interview Survey. Mayo. Clin. Proc., 2007, 82(5), 561-566.
32. Foti, R.S.; Wahlstrom, J.L. Prediction of CYP-mediated drug interactions in vivo using in vitro data. Idrugs., 2008, 11(12), 900-905.
33. Hyland, R.;Dickins, M.;Collins, C.;Jones, H.; Jones, B. Maraviroc: in vitro assessment of drug-drug interaction potential. Brit. J. Clin. Pharmaco., 2008, 66(4), 498-507.
34. Umehara, K.I.; Susaki, Y.; Van Teylingen, R.H. J.; Neat, J.N.; Ndikum-moffor, F.; Noguci, K.;Usui, T.; Parkinson, A.; Kamimura, H. Evaluation of the inhibitory and induction potential of YM758, a novel If channel inhibitor, for human P450-mediated metabolism. Eur. J. Drug. Metab. Pharmcokinet., 2008, 33(4), 211-223.
35. Li, Z.Y.; Li, Q.; Lv, J.; Ling, J.H.; Yu, X.H, Chen, X.H.; Bi, K.S. LC-MS determination and pharmacokinetic study of salidroside in rat plasma after oral administration of suspensions of traditional Chinese medicine Erzhi Wan and Fructus Ligustri lucidi. J. Pharm. Anal., 2011, 1(1), 8-12.
36. Mulder, G.J. Glucuronidation and its role in regulation of biological activity of drugs. Annu. Rev. Pharmacol., 1992, 32(1), 25-49.
37. Zhang, X.; Yao, Y.; Lou, Y.; Jiang, H.D.; Wang, X.W.; Chai, X.J.; Zeng, S. Metabolismof ebracteolata compound B studied in vitro with human liver microsomes, HepG2 cells, and recombinant human enzymes. Drug Metab. Dispos., 2010, 38(12), 2157-2165.
38. Lu, Y.; Zhu, J.; Chen, X.J.; Li, N.; Fu, F.F.; He, J.K.; Wang, G.J.; Zhang, L.L.; Zheng, Y.; Qiu, Z.X.; Yu, X.; Han, D.; Wu, L.Identification of human UDP-Glucuronosyltransferase isoforms responsible for the glucuronidation of Glycyrrhetinic Acid. Drug Metab. Pharmacok., 2009, 24(6), 523-528.
39. He, Y.Q.; Liu, Y.; Zhang, B.F.; Liu, H.X.; Lu, Y.L.; Yang, L.; Xiong, A.Z.;Xu, L.L.; Wang, C.H.; Wang, Z.T. Identification of the UDP- Glucuronosyltransferase Isozyme Involved in Senecionine Glucuronidation in Human Liver Microsomes. Drug Metab. Dispos., 2010, 38(4), 626-634.
40. Liang, S.C.;Ge, G.B.;Liu, H.X.;Zhang, Y.Y.;Wang, L.M.;Zhang, J.W.;Yin, L.;Li, W.;Fang, Z.Z.;Wu, J.J.;Li, G.H.; Yang, L. Identification and Characterization of Human UDPGlucuronosyltransferases Responsible for the In vitro Glucuronidation of daphnetin. Drug Metab. Dispos., 2010, 38(6), 973-980.
41. Liu, H.X.; Liu, Y.; Zhang, J.W.; Li, W.; Liu, H.T. ;Yang, L.UDPglucuronosyltransferase 1A6 is the major isozyme responsible for protocatechuic aldehyde glucuronidation in human liver microsomes. Drug Metab. Dispos., 2008, 36(8), 1562-1569.
42. Zhu, L.L.; Ge, G.B.; Zhang, H.B.; Liu, H.X.; He, G.Y.; Liang, S.C.;Zhang, Y.Y.; Fang, Z.Z.; Dong, P.P.; Finel.Moshe.; Yang, L. Characterization of hepatic and intestinal glucuronidation of magnolol: application of the RAF approach to decipher the contributionsof multiple UGT isoforms. Drug Metab. Dispos., doi:10.1124/dmd.111.04219
43. Otake, Y.;Hsieh, F.; Walle, T. Glucuronidation versus oxidation of the flavonoid galangin by human liver microsomes and hepatocytes. Drug Metab. Dispos., 2002, 30(5), 576-581.
44. Galijatovic, A.;Otake, Y.;Walle, U.K.; Walle, T. Extensive metabolism of the flavonoid chrysin by human Caco-2 and HepG2 cells. Xenobiotica, 1999, 29(12), 1241-1256.
45. Yodogawa, S.; Arakawa, T.; Sugihara, N.; Furuno, K. Glucuronoand sulfo-conjugation of Kaempferol in rat liver subcellular preparations and cultured hepatocytes. Biol. Pharm. Bull., 2003, 26(8), 1120-1124.
46. Chen, Y.K.; Xie, S.G; Chen, S.Q.; Zeng, S. Glucuronidation of flavonoids by recombinant UGT1A3 and UGT1A9. Biochem. Pharmacol., 2008, 76(3), 416-425.
47. Chen, Y.K.; Chen, S.Q., Li, X.; Zeng, S. Quantitativeregio selectivity of glucuronidation of quercetin by recombinant UDPglucuronosyltransferases 1A9 and1A3 using enzymatic kinetic parameters. Xenobiotica, 2005, 35(10-11), 943-954.
48. Xie, S.G.;You, L.Y.; Zeng, S. Studies on the flavonoid substrates of human UDP-glucuronosyl transferase UGT 2B7. Pharmazie, 2007, 62(8), 625-629.
49. Iwai, M.; Maruo, Y.; Ito, M.; Yamamoto, K.; Sato, H.; Takeuchi, Y. Six novel UDP-glucuronosyltransferase (UGT1A3) polymorphisms with varying activity. J. Hum. Genet., 2004, 49(3), 123-128.
50. Oken, B.S.; Storzbach, D.M.; Kaye, J.A. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch. Neurol., 1998, 55(11), 1409-1415.
51. Hasler, A.; Gross, G.A.; Meier, B.; Sticher, O. Complex flavonol glycosides from the leaves of ginkgo-biloba. Phytochem., 1992, 31(4), 1391-1394.
52. Chan, P.C.; Xia, Q.; Fu, P.P. Ginkgo biloba leave extract: biological, medicinal, and toxicological effects. J. Environ. Sci. Health. C Environ. Carcinog. Ecotoxicol. Rev., 2007, 25(3), 211-244.
53. Moon, Y.J.;Wang, X.D.; Morris, M.E. Dietary flavonoids: Effects on xenobiotic and carcinogen metabolism. Toxicol. In vitro., 2006, 20(2), 187-210.
54. Barve, A.; Chen, C.; Hebbar, V.; Desiderio, J.; Saw, C.L.; Kong, A.N. Metabolism, Oral Bioavailability and Pharmacokinetics of Chemopreventive Kaempferol in Rats. Biopharm. Drug Dispos., 2009, 30(7), 356-365.
55. O .Oliveira, E.J.; Watson, D.G. In vitro glucuronidation of kaempferol and quercetin by human UGT1A9 microsomes. FEBS. Lett. , 2000, 471(1), 1-6.
56. Gaster, B.; Holroyd, J. St John's wort for depression: a systematic review. Arch. Intern. Med., 2000, 160(2), 152-156.
57. Butterweck ,V; Schmidt, M. St. John's wort: role of active compounds for its mechanism of action and efficacy. Wien. Med. Wochenschr., 2007, 157(13-14), 356-361.
58. Fujiki, H., Suganuma, M.; Imai, K.; Nakachi, K. Green tea: cancer preventive beverage and/or drug. Cancer Lett., 2002,188(1-2), 9-13.
59. Imai, K.; Suga, K.; Nakachi, K. Cancer-preventive effects of drinking green tea among a Japanese population. Prev. Med., 1997, 26(6), 769-775.
60. Cabrera, C.; Artacho, R.; Giménez , R. Beneficial effects of green tea-a review. J. Am. Coll. Nutr.,2006, 25(2), 79-99.
61. Gupta, S.; Saha, B.; Giri ,AK. Comparative antimutagenic and anticlastogenic effects of green tea and black tea: a review. Mutat. Res., 2002, 512(1) 37-65.
62. Feng ,W.Y. Metabolism of green tea catechins: an overview. Curr. Drug Metab., 2006, 7(7), 755-809.
63. Lu, H.; Meng, X.; Li, C.; Sang, S.; Patten, C.; Sheng, S.; Hong, J.; Bai, N.; Winnik, B.; HoC, T.; Yang ,C.S. Glucuronides of tea catechins: enzymology of biosynthesisand biological activities. Drug Metab. Dispos., 2003, 31(4), 452-461.
64. Dhiman, R.; Chawla, Y. Herbal medicines for liver diseases.Dig. Dis. Sci., 2005, 50(10), 1807-1812.
65. Flora, K.; Hahn, M.; Rosen, H.; Benner, K. Milk thistle (Silybum marianum) for the therapy of liver disease. Am. J. Gastroenterol., 2004, 93(2), 139-143.
66. Miranda, S.R.; Lee, J.K.; Brouwer, K.L.; Wen, Z.; Smith, P.C.; Hawke, R.L. Hepaticmetabolism and biliary excretion of silymarin flavonolignans in isolatedperfused rat livers: role of multidrug resistance-associated protein2 (Abcc2). Drug Metab. Dispos., 2008, 36(11), 2219-2226.
67. Hoh, C.; Boocock, D.; Marczylo, T.; Singh, R., Berry, D.P.; Dennison, A.R.; Hemingway, D.; Miller, A.; West, K.; Euden, S.; Garcea, G.; Farmer, P.B.; Steward, W.P.; Gescher, A.J. Pilot study of oral silibinin, a putative chemopreventiveagent, in colorectal cancer patients: silibinin levels in plasma, colorectum,and liver and their pharmacodynamic consequences. Clin. Cancer Res., 2006, 12(9), 2944-2950.
68. Matal, J.; Jancova, P.; Siller, M., Masek, V., Anzenbacherova, E.; Anzenbacher, P. Interspecies comparison of the glucuronidation processes in the man, monkey, pig, dog and rat. Neuro. Endocrinol. Lett., 2008, 29(5), 738-743.
69. Zhu, M.; Yao, T.W.; Zeng, S. Glucuronidation and in vitro interaction of Ginkgo flavonoids with other drugs. J. Zhejiang Univ. Med. Sci., 2004, 33(1), 15-20.
70. Sun, X.Y.; Plouzek, C.A.; Henry, J.P.; Wang, T.T.; Phang,.J.M. Increased UDP-glucuronosyl transferase activity and decreased prostate specific antigenproduction by biochanin A in prostate cancer cells. Cancer Res., 1998, 58(11), 2379-2384.
71. Galijatovic, A.; Otake, Y.; Walle, U.K.; Walle, T. Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in Caco-2 cells -Potential role in carcinogen bioinactiviation. Pharm. Res., 2001, 18(3), 374-379.
72. Mohamed, M.E.F.; Frye, R.F. Inhibition of intestinal and hepatic glucuronidation of mycophenolic acid by Ginkgo biloba extract and flavonoids. Drug Metab. Dispos., 2010, 38(2), 270-275.
73. Allison, A.C.; Eugui, E.M. Mechanisms of action of mycophenolate mofetilin preventing acute and chronic allograft rejection. Transplantation., 2005, 80(2), S181-S190.
74. Heatwole, C.; Ciafaloni, E. Mycophenolate mofetil for myasthenia gravis:a clear and present controversy. Neuropsychiatr. Dis. Treat., 2008, 4(6), 1203-1209.
75. Picard, N.; Ratanasavanh, D.; Premaud, A.;Le Meur, Y.; Marquet, P. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab. Dispos., 2005, 33(1), 139-146.
76. Moon, Y.J.; Wang, L.; Di Cenzo, R.; Morris, M.E. Quercetin pharmacokinetics in humans. Biopharm. Drug Dispos., 2008, 29(4), 205-217.
77. Hellum, B.H.; Hu, Z.; Nilsen, O.G. The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes. Clin. Pharmacol. Toxicol., 2007, 100(1), 23-30.
78. Staatz, C.E.; Tett, S.E. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin. Pharmacokinet., 2007, 46(1), 13-58.
79. Borrelli, F.; Izzo, A.A. Herb-Drug Interactions with St John's Wort (Hypericum perforatum): an Update on Clinical Observations. AAPS. J., 2009, 11(4), 710-727.
80. Volak L. Role for protein kinase C delta in the functional activity of humanUGT1A6: implications for drug-drug interactions between PKC inhibitors and UGT1A6. Xenobiotica, 2010, 40(5), 306-318.
81. Schulz, H.U.; Schurer, M.; Bassler, D.; Weiser, D. Investigation of pharmacokinetic data of hypericin, pseudohypericin, hyperforin and the flavonoidsquercetin and isorhamnetin revealed from single and multipleoral dose studies with a Hypericum extract containing tablet inhealthy male volunteers. Arzneimittel. Forsch., 2005, 55(10), 561-568.
82. Hu, Z.P.; Yang, X.X.; Chen, X.; Cao, J.; Chan, E.; Duan, W.; Huang, M.; Yu, X.Q,; Wen, J.Y,; Zhou, S.F. A mechanistic study on altered pharmacokinetics of irinotecanby St. John's wort. Curr. Drug Metab., 2007, 8(2), 157-171.
83. Venkataramanan, R.; Ramachandran, V.; Komoroski, B.J.; Zhang, S.; Schiff, P.L.; Strom, S.C. Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in humanhepatocyte cultures. Drug Metab. Dispos., 2000, 28(11), 1270-1273.
84. Jancova, P.; Siller, M.; Anzenbacherova, E.; Kren, V.; Anzenbacher, P.; Simanek, V. Evidence for differences in regioselective and stereoselective glucuronidation of silybin diastereomers from milk thistle (Silybum marianum) by human UDPglucuronosyltransferases. Xenobiotica, 2011, 41(9), 743-751.
85. Williams, J.A.; Ring, S.A. Differential. Modulation of UDPglucuronosyltransferase1A1( UGT1A1)-catalyzed estradiol-3- glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes. Drug Metab. Dispos., 2002, 30(11), 1266-1273.
86. Bernard, H. The direct and indirect effects of herbal products on common drug metabolizing enzymes and drug transporters. PhD Thesis, University of Pittsburgh: October 2005.
87. Mohamed, M.F.; Tseng, T.; Frye, R.F. Inhibitory effects of commonly used herbal extracts on UGT1A1 enzyme activity. Xenobiotica, 2010, 40(10), 663-669.
88. Sridar, C.; Goosen, T.C.; Kent, U.M.; Williams, J.A.; Hollenberg, P.F. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab. Dispos., 2004, 32(6), 587-594.
89. Van Erp, N.P.; Baker, S.D.; Zhao, M.; Rudek; M.A.; Guchelaar, H.J., Nortier J.W.; Sparreboom, A.; Gelderblom, H. Effect of milk thistle (Silybum marianum)on the pharmacokinetics of irinotecan. Clin. Cancer Res., 2005, 11(21), 7800-7806.
90. De Lemons, M.D. Effects of soy phytoestrogens genistein and daidzein on breast cancer growth. Ann. Pharmacother., 2001, 35(9), 1118-1121.
91. Messina, M.; Bennink, M. Soyfoods, isoflavones and risk of colonic cancer: a review of the in vitro and in vivo data. Baillieres. Clin. Endocrinol. Metab., 1998, 12(4), 707-728.
92. Anthony, M.S.; Clarkson, T.B.; Williams, J.K. Effects of soy isoflavones on atherosclerosis: potential mechanisms. Am. J. Clin. Nutr., 1998, 68(6), 1390S-1393S.
93. Pfeiffer, E.; Treiling, C.R.; Hoehle, S.I.; Metzler, M. Isoflavones modulate the glucuronidation of estradiol in human liver microsomes. Carcinogenesis, 2005, 26(12), 2172-2178.
94. Court, M.H. Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases. Method Enzymol., 2005, 400(1), 104-116.
95. Anderson, G.D.; Rosito, G.; Mohustsy, M.A.; Elmer, G.W. Drug interaction potential of soy extract and Panax ginseng. J. Clin. Pharmacol., 2003, 43(6), 643-648.
96. Froyen, E.B.; Reeves, J.L.R.; Mitchell, A.E.; Steinberg, F.M. Regulation of Phase II Enzymes by Genistein and Daidzein in Male and Female Swiss Webster Mice. J. Med. Food., 2009, 12(6), 1227-1237.
97. Nikaidou, S.; Ishizuka, M.; Maeda, Y.; Hara, Y.; Kazusaka, A.; Fujita, S. Effect of components of green tea extracts, caffeine and catechins on hepatic drug metabolizing enzyme activities and mutagenic transformation of carcinogens. Jap. J. Veter. Res., 2005, 52(4), 185-192.
98. Bu-Abbas, A.; Clifford, M.N.; Walker, R. Ioannides, C. Contribution of caffeineand flavanols in the induction of hepatic phase II activities by green tea. Food Chem. Toxicol., 1998, 36(8), 617-621.
99. Zhu, B.T.; Taneja, N.; Loder, D.P.; Balentine, D.A.; Conney, A.H. Effects of teapolyphenols and flavonoids on liver microsomal glucuronidation of estradiol and estrone. J. Steroid Biochem. Mol. Biol., 1998, 64(4), 207-215.
100. Foster, D.R.; Sowinski, K.M.; Chow, H.H.; Overholser, B.R. Limited sampling strategies to estimate exposure to the green tea polyphenol, epigallo catechin gallate, in fasting and fed conditions. Ther. Drug Monit., 2007, 29(6), 835-841.
101. Mirkov, S.; Komoroski, B.J; Ramirez, J,; Graber, A.Y.; Ratain, M.J.; Strom, S.C.; Innocenti, F. Effects of green tea compounds on irinotecan metabolism., Drug Metab. Dispos., 2007, 35(2), 228-231.
102. Sobota, A.E. Inhibition of bacterial adherence by cranberry juice: potential use for the treatment of urinary tract infections. J. Urology., 1984, 131(5), 1013-1016.
103. Hakkinen, S.H.; Karenlampi, S.O; Heinonen, I.M; Mykkanen, H.M.; Torrone, A.R. Content of the flavonols quercetin, myricetin, and kaempferol in 25 edible berries. J. Agric. Food Chem., 1999, 47(6), 2274-2279.
104. Neto, C.C. Cranberry and its phytochemicals: a review of in vitro anticancer studies. J. Nutr., 2007, 137(1), 186S-193S.
105. Hebbar, V.; Shen, G.X.; Hu, R.; Kim, B.R.; Chen, C.; Korytko, P.J.; Crowell, J.A.; Levine, B.S.; Kong, A.N.T. Toxicogenomics of resveratrol in rat liver. Life Sci., 2005, 76(20), 2299-2314.
106. Chow, H.H.S.; Garland, L.L.; Hsu, C.-H.; Vining, D.R.; Chew, W.M.; Miller, J.A.; Perloff, M.; Crowell, J.A.; Alberts, D.S. Resveratrol Modulates Drug and Carcinogen-Metabolizing Enzymes in a Healthy Volunteer Study. Cancer Preve. Res., 2010, 287(3), 1168-1175.
107. Xie, W.; Evans, R.M. Orphan nuclear receptors: The exotics of xenobiotics. J. Biol. Chem., 2001, 276(41), 37739-37742.
108. Tolson, A.H.; Wang, H. Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR. Adv. Drug Deliver. Rev., 2010, 62(13), 1238-1249.
109. Ihunnah, C.A.; Jiang, M.; Xie, W. Nuclear receptor PXR, transcriptional circuits and metabolic relevance. BBA-Mol. Basis. Dis., 2011, 1812(8) , 956-963.
110. Liddle, C.; Goodwin, B. Regulation of hepatic drug metabolism: Role of the nuclear receptors PXR and CAR. Semin. Liver Dis., 2002, 22(2), 115-122.
111. Yu, C.N.; Chai, X.J.; Yu, L.S.; Chen, S.Q.; Zeng, S. Identification of novel pregnane X receptor activator traditional Chinese medicines. J. Ethnopharmacol., 2011, 136(1), 137-143.
112. Wang, J.Y.; Yu, L.S.; Zeng, S. Establishment of hPXR mediated reporter gene model for UGT1A1 and its application. Chinese. J. Pharm. Sci., 2012. [Epub Ahead of Print]
113. Huang, W.D.; Zhang, J.; Moore, D.D. A traditional herbal medicine enhances bilirubin clearance by activating the nuclear receptor CAR. J. Clin. Inves., 2004, 113(1) , 137-143.
114. Bonzo, J.A.; Belanger, A.; Tukey, R.H. The role of chrysin and the Ah receptor in induction of the human UGT1A1 gene in vitro and in transgenic UGT1 mice. Hepatol., 2007, 45(2), 349-360.
115. Sugatani, J.; Yamakawa, K.; Tonda, E.; Nishitani, S.; Yoshinari, K.; Degawa, M.; Abe, I.; Noguchi, H.; Miwa, M. The induction of human UDP-glucuronosyltransferase 1A1 mediated through a distal enhancer module by flavonoids and xenobiotics. Biochem. Pharmacol., 2004, 67(5), 2291-2292.
116. Walle, U.K.; Walle, T. Induction of human UDP-glucuronosyl transferase UGT1A1 by flavonoids-structural requirements. Drug Metab. Dispos., 2002, 30(5), 564-569.
117. Chlouchi, A.; Girard, C.; Bonet, A.; Viollon-Abadie, C.; Heyd, B.; Mantion, G.; Martin, H.; Richert, L. Effect of chrysin and natural coumarins on UGT1A1 and 1A6 activities in rat and human hepatocytes in primary culture. Planta Med., 2007, 73(8), 742-747.
118. Shipkova, M.; Wieland, E. Glucuronidation in the rapeutic drug monitoring. Clin. Chim. Acta., 2005, 358(2) , 2-23.
119. Kiang, T.K.; Ensom, M.H.; Chang, T.K. UDP-glucuro-nosyl transferases and clinical drug-drug interactions. Pharmacol. Ther., 2005, 106(1), 97-132.
120. Miners, J.O.; Mackenzie, P.I.; Knights, K.M. The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential. Drug Metab. Rev., 2010, 42(1), 196-208.